<DOC>
	<DOCNO>NCT01959919</DOCNO>
	<brief_summary>This study aim investigate prospectively throughout period 3- 6 month exceed 12 month ( accord local therapeutic plan ) patient experience treatment Factor VIII new device name FuseNGO , new delivery system Factor VIII compare previous delivery system .</brief_summary>
	<brief_title>Evaluation Of Acceptability And Satisfaction Of Hemophilia Patients Treated With FusENGO</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<criteria>Male adult ( age 18 65 year ) Haemophilia A ( severity level ) currently use FVIII treatment either prophylactically ondemand use traditional factor VIII delivery mechanism . Patients advise reason physician switch new factor VIII delivery device , namely FuseNGO , receive detail study Patients request treated new factor VIII delivery device namely FuseNGO , receive detail study . Patients previously recommend physician switch new factor VIII delivery system Patients previously ask physician switch new factor VIII delivery system . Patients anticipate 10 infusion occur 12 month follow inclusion study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>